^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study

Published date:
06/12/2020
Excerpt:
Higher than median levels of three serum markers were negatively associated with the 2-year LRC rate in the overall patient cohort: Osteopontin, IL8 and FasL2 (p≤0.05).
DOI:
10.1016/j.radonc.2020.06.011